MAPT and Alzheimer disease: In cellular models of AD, treatment with the bioactive hexamers attenuated the acute aberrant effects of Aβ on hippocampal synapses as well as limiting neuronal cell death and tau phosphorylation induced by chronic exposure to Aβ [29].